Pharmaceutical Executive Europe - May 2008 - (Page 6)

6 News & Analysis May 2008 Pharmaceutical Executive Europe News & Analysis For more on these news stories and all the latest breaking pharma news, look at our website www.pharmexeceurope.com, which now features daily updates, interactive surveys and dedicated sections for your particular area of interest. NEWS Symbicort patent revoked AstraZeneca has been told that its patents for Symbicort (formoterol/budesonide), as a treatment for chronic obstructive pulmonary disease (COPD), are no longer valid in Europe. A final ruling has been made by the European Patent Office’s Technical Board of Appeal, that the European Combination Patent covering the use of Symbicort for COPD has been revoked, following an appeal by Norton Healthcare and Generics UK. The patent is one of two covering the Symbicort combination in 22 countries, and was originally due to expire in 2018. The second patent is also currently being disputed. Worldwide sales of Symbicort reached $1.58 billion in 2007, with Europe accounting for $1.34 billion. EUSA acquires Cytogen EUSA Pharma has completed its acquisition of Cytogen Corporation, following approval by Cytogen’s shareholders. Under the terms of the agreement, which valued the company at $22.6 million, Cytogen shareholders will receive $0.62 per share. In order to meet the consideration, EUSA raised more than $50 million in an GSK acquires Sitris Pharmaceuticals GlaxoSmithKline (GSK) has taken over Sitris Pharmaceuticals as part of an investment round led by TVM Capital and supported by EUSA’s existing investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. EUSA’s next step will to apply to delist all Cytogen’s issued shares from the NASDAQ stock exchange. Upon completion of the acquisition, Cytogen will become a wholly-owned subsidiary of EUSA and will bring with it three oncology and pain control products, a US sales force and a well established commercial infrastructure. Speaking about the deal, Bryan Morton, chief executive of EUSA Pharma said: “Completing our acquisition of Cutogen is particularly significant for EUSA as it also completes our transatlantic growth platform, positioning us as a partner of choice for further acquisitions and product in-licensing.” Webcast to address the new pharma sales models Green light for BI’s HIV treatment Boehringer Ingelheim has been granted full marketing authorisation by the European Commission for its HIV protease inhibitor (PI), Aptivus (tipranavir). Aptivus is the first non-peptidic PI treatment to show good antiviral activity during trials. More than 1400 patients were enrolled in two studies, Resist I and II, the largest evaluation to be carried out on treatmentsponsored by agreement involving the acquisition of the company’s research portfolio. The deal, which sees GSK paying Sitris $720 million (£362 million), is part of a move to enhance GSK’s metabolic, neurological, immunological and inflammation research capabilities. Sitris will become part of GSK’s drug discovery organisation and is expected to continue operating as an autonomous research unit from its facility in Massachusetts, US. Commenting on the deal, Chairman of GSK R&D, Moncef Slaoui said: “This acquisition continues GSK’s strategy of pursuing the best new science, externally or internally, to bring new medicines to patients and value to the GSK pipeline. Our intent is to retain all Sitris employees and continue the entrepreneurial and innovative culture they created.” Pfizer to set site on Ireland Pfizer is to invest E190million in a new biotech plant in Ireland for the production of experimental medicines. The facility will develop and produce small-scale quantities of products for Phase II and III clinical trials and is likely to create around 100 permanent jobs over a threeyear period. A further 500 people will be employed during construction of the plant. Located at Shanbally in County Cork, the facility is due to open by the end of 2009. Court rules against NICE The Court of Appeal in England has ruled that the National Institute for Health and Clinical Excellence (NICE) was insufficiently transparent when disclosing why it had decided to limit access to Alzheimer’s drugs. NICE ruled that four drugs (Aricpet, Exelon, Reminyl and Ebixa) were not cost-effective and should, therefore, not be funded by the NHS. Lord Justice Richards, who presided over the appeal, said that by not releasing the model used to make the decision, NICE had put those who wished to challenge the decision at a “significant disadvantage.” “Today’s decision is a damning indictment of the fundamentally flawed process used by NICE to deny people with Alzheimer’s disease access to drug treatments,” remarked Neil Hunt, chief executive of the UK Alzheimer’s Society. “The decision must now be urgently revisited to ensure everyone with Alzheimer’s disease is given access to these drug treatments on the NHS, which cost just £2.50 per person per day,” he urged. info@clinphone.com www.clinphone.com experienced patients. “This full approval demonstrates the confidence that the authorities have in the benefit of Aptivus for patients with a resistant virus,” commented Dr Andrea Barner, board member of Boehringer. http://www.pharmexeceurope.com http://www.clinphone.com http://www.clinphone.com

Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - May 2008

Pharmaceutical Executive Europe - May 2008
Contents
From the Editor
News and Analysis
Calendar
Rising in the East
Use Your Strategic Discretion
A Blueprint for Success
Market Access and the Patient
Activating Effective Product Differentiation
What Doctors Want
IC Success in Four Steps

Pharmaceutical Executive Europe - May 2008

http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201302
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201301
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201212
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201211
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201210
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201209
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201208
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201207
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201206
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201205
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201204
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201203
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201202
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201201
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201112
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201111
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201110
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_201109
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110823
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110809
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110728_v2
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110728
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110711
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110624
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110609
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110526
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110512
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_oracle_201105
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110426
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110412
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110324
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110310
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110224
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110208
http://digital.findpharma.com/nxtbooks/advanstaruk/pegd_20110128
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_mediakit2011
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20101216
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20101124
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20101111
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20101027
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20101013
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100930
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100915_supp
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100915
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100825
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100811
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100727
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100713
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100623
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100609
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100526
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100512
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_ims_201005
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100427
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100414
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100324
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100310
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100224
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100210
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100126
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20100112
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091222
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091208
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091124
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091110
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091027
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20091013
http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_DIGEST_20090930
http://digital.findpharma.com/nxtbooks/advanstaruk/PEE_digest_20090916
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090902
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090825
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090819
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090812
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090805
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090729
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090721
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090715
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090708
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090701
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090624
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090617
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090610
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090602
http://digital.findpharma.com/nxtbooks/advanstaruk/pee_digest_20090526
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090519
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090512
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090505
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_southafrica
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090429
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090422
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090415
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090408
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401_v2
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090401
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090325
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090318
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090311
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090304
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090224
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090218
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090211
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090203
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090128
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090121
https://www.nxtbook.com/nxtbooks/advanstaruk/pee_digest_20090114
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1208
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1108
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1008
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1008
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0908
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0808
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0708
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0608
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0508
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0508
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0408
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0308
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0208
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imssales0208
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0108
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-ims1207
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1107
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1007
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope-imsoncology0907
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0407
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope0307
https://www.nxtbook.com/nxtbooks/advanstaruk/pharmexeceurope1206
https://www.nxtbookmedia.com